Details, Fiction and XMU-MP-1
Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in comparison with imatinib, for the very first-line procedure of CML-CP. 5 hundred and nineteen individuals with newly diagnosed CML-CP have been randomly assigned to receive dasatinib in a dose of 100 mg the moment everyday (259 individuals) or imatinib in a dose of 400 mg a